Companies /Healthcare

Corbus Pharmaceuticals Holdings Inc

NASDAQ: CRBP Biotechnology
$5.49
▼ $0.29 (−5.02%) today
Markets closed · 9:28pm ET

CRBP at a Glance

Valuation
Market cap
$111.8M
Profitability
EPS (TTM)
$-6.11
Price
52-week range
$5 – $21
Street target
$34.02
Earnings
Next report
Nov 11, 2026

Headquartered in Norwood, MA Fiscal year ends December NASDAQ: CRBP corbuspharma.com

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity. The company's pipeline includes CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate (ADC) licensed from CSPC Megalith Biopharmaceutical, being developed for oropharyngeal squamous cell carcinoma and cervical cancer, with FDA Fast Track designations for both indications. The second pipeline asset is CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity, designed with a mechanism of action distinct from the GLP-1 receptor agonist class. The company is pre-revenue and funds operations through equity capital, with a cash runway expected into 2028. Corbus trades on NASDAQ under the ticker CRBP. Updated

CRBP Coverage

Frequently Asked Questions

What does Corbus Pharmaceuticals do?

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity.

What is the CRBP stock price target?

The Wall Street consensus 12-month price target for CRBP is $34.02.